false 0001506983 0001506983 2026-08-18 2026-08-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 18, 2026

 

GLUCOTRACK, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41141   98-0668934
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

301 Rte. 17 North, Ste. 800, Rutherford, NJ   07070
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (201) 842-7715

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   GCTK   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

Summary of Proposals Submitted to Stockholders

 

On August 18, 2026, Glucotrack, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the following proposals were submitted to the stockholders of the Company, as set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on July 17, 2026:

 

Proposal 1:   The election of six directors, each to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.
     
Proposal 2:   The approval, on an advisory basis, of the 2025 executive compensation of the Company’s named executive officers (“Say-on-Pay”).
     
Proposal 3:   The ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
     
Proposal 4:   The approval of one or more amendments to the Company’s certificate of incorporation (as amended, the “Certificate of Incorporation”) to effect one or more reverse stock splits of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an aggregate ratio not to exceed one-for-thirty (the “Reverse Stock Split”).
     
Proposal 5:   The approval of a proposed warrant inducement, including the repricing of certain existing warrants and the issuance of new inducement warrants to the holders of such existing warrants and the issuance of shares of Common Stock upon exercise thereof, for purposes of complying with Nasdaq Listing Rule 5635(d) (the “Warrant Inducement”).

 

Voting Results

 

On the record date, there were 7,719,121 shares of Common Stock issued and outstanding. Of the 7,719,121 votes that were eligible to be cast by the holders of the Common Stock at the Annual Meeting, 2,786,974 votes, or approximately 36.10% of the total, were represented at the meeting in person or by proxy, constituting a quorum. The number of votes cast for, against or withheld, as well as abstentions and broker non-votes, if applicable, in respect of each such matter is set forth below:

 

Proposal 1: Election of Directors.

 

The Company’s stockholders elected the following directors to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified. The votes regarding the election of these directors were as follows:

 

Director Nominee   Votes For   Votes Against   Abstentions   Broker Non-Votes
Andrew K. Balo   960,882   75,038   83,448   1,667,606
Victoria Carr-Brendel   960,826   75,088   83,454   1,667,606
Erin Carter   960,573   75,278   83,517   1,667,606
Erik Emerson   961,363   74,550   83,455   1,667,606
Paul V. Goode   934,050   134,410   50,908   1,667,606
Luis Malavé   960,650   75,211   83,507   1,667,606

 

 

 

 

Proposal 2: Advisory Vote on Executive Compensation (Say-on-Pay).

 

The Company’s stockholders approved, on an advisory basis, the 2025 executive compensation of the Company’s named executive officers. The votes regarding this proposal were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
962,623   122,785   33,960   1,667,606

 

Proposal 3: Ratification of the Appointment of CBIZ CPAs P.C.

 

The Company’s stockholders ratified the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes regarding this proposal were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
2,621,952   134,874   30,148  

 

Proposal 4: Approval of the Reverse Stock Split.

 

The Company’s stockholders approved the proposal to amend Article IV of the Certificate of Incorporation to effect one or more Reverse Stock Splits at an aggregate ratio not to exceed one-for-thirty. The votes regarding this proposal were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
2,099,338   674,484   13,152  

 

Proposal 5: Approval of the Warrant Inducement.

 

The Company’s stockholders approved the Warrant Inducement, including the repricing of certain existing warrants and the issuance of new inducement warrants to the holders of such existing warrants and the issuance of shares of Common Stock upon exercise thereof, for purposes of complying with Nasdaq Listing Rule 5635(d). The votes regarding this proposal were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
895,306   138,265   85,797   1,667,606

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 19, 2026    
     
  GLUCOTRACK, INC.
     
  By: /s/ Erik Emerson
  Name: Erik Emerson
  Title: Chief Executive Officer

 

 

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

XBRL SCHEMA FILE

XBRL LABEL FILE

XBRL PRESENTATION FILE

IDEA: R1.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: form8-k_htm.xml